Radiotherapy with Gemcitabine for Pancreatic Cancer
Author Information
Author(s): Okusaka T, Ito Y, Ueno H, Ikeda M, Takezako Y, Morizane C, Kagami Y, Ikeda H
Primary Institution: National Cancer Center Hospital, Tokyo, Japan
Hypothesis
Does the combination of radiotherapy and gemcitabine improve survival in patients with locally advanced pancreatic cancer?
Conclusion
The study found that while the combination of radiotherapy and gemcitabine has moderate activity against locally advanced pancreatic cancer, it is associated with significant acute toxicities and a high rate of distant metastasis.
Supporting Evidence
- 42 patients were enrolled in the study.
- 9 patients achieved a partial response to treatment.
- 26 patients had stable disease after treatment.
- Median survival time was 9.5 months.
- Acute toxicity was observed in a significant number of patients.
Takeaway
Doctors tested a new treatment for pancreatic cancer using radiation and a drug called gemcitabine. They found it helped some patients, but many still got worse quickly.
Methodology
Patients with locally advanced pancreatic cancer received radiotherapy and gemcitabine, with eligibility criteria including specific health conditions and performance status.
Potential Biases
Potential bias due to the non-randomized nature of the study and the specific patient selection criteria.
Limitations
The study had a small sample size and a high rate of treatment discontinuation due to toxicity.
Participant Demographics
{"gender":{"male":19,"female":23},"age":{"median":59,"range":"43-73"},"ECOG_performance_status":{"0":12,"1":30}}
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website